Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients

Area of Science:

• Neurology
• Neuroimmunology
• Neurodegenerative Diseases

Background:

• Increasing life expectancy in multiple sclerosis (MS) necessitates understanding co-occurring health conditions.
• Atypical presentation of Alzheimer disease dementia in MS patients prompted further investigation.
• Alzheimer disease pathology is characterized by amyloid-β accumulation.

Purpose of the Study:

• To investigate the prevalence of Alzheimer disease pathology in patients with multiple sclerosis.
• To determine if MS is associated with a reduced risk of Alzheimer disease.

Main Methods:

• Compared amyloid-β plasma biomarker positivity rates between 100 MS patients and 300 matched non-MS controls.
• Controlled for age, sex, apolipoprotein E proteotype, and cognitive status in the comparison groups.
• Examined the clinical features of MS patients with positive amyloid-β biomarker results.

Main Results:

• Amyloid-β plasma biomarker positivity was approximately half as common in MS patients compared to controls.
• MS patients with detected amyloid-β pathology often presented with atypical features at diagnosis.
• These findings indicate a potential protective association between MS and Alzheimer disease.

Conclusions:

• Multiple sclerosis is associated with a reduced risk of developing Alzheimer disease.
• The study suggests novel research directions into the interplay between MS and Alzheimer disease pathogenesis.
• Understanding this relationship may lead to new therapeutic strategies for both conditions.